What Wall St. Knows About Applied UV Today.

During the morning session, Applied UV moved 57.7%, compared to 0.1% for the S&P 500.

Applied UV, Inc., through its subsidiaries, develops, acquires, and commercializes technology that addresses air purification and infection control in the healthcare, hospitality, commercial, municipal, and residential markets in the United States, Canada, and Europe. Based in Mount Vernon, the company has 61 full time employees and a market cap of $21,020,207.

The company is now trading -67.2% away from its average analyst target price of $5 per share. The 2 analysts following the stock have set target prices ranging from $2 to $8, and on average give Applied UV a rating of buy.

Over the last year, AUVI shares have gone down by -40.2%, which represents a difference of -31.8% when compared to the S&P 500. The stock's 52 week high is $4.2 per share and its 52 week low is $0.83. Based on Applied UV's average gross margin growth of 24.5% over the last four years, its core business remains strong. However prospective investors should keep an eye on the company's negative cash flows.

2019-12-31 2020-12-31 2021-12-31
Revenue (k) $9,330 $5,733 $11,668
Revenue Growth n/a -38.55% 103.53%
Gross Margins 35.6% 17.6% 35.1%
Gross Margins Growth n/a -50.56% 99.43%
Operating Margins 15.0% -57.8% -62.5%
Operating Margins Growth n/a -485.33% -8.13%
Earnings Per Share $0.44 -$0.59 -$0.86
EPS Growth n/a -234.09% -45.76%
Free Cash Flow (k) $757 -$876 -$7,027
FCF Growth n/a -215.66% -702.31%
Capital Expenditures (k) -$13 -$219 -$29
LT Debt to Equity 0.09 0.03 0.0
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.